Biotech Values

[oc631]

companies will do annual price increases that tweak and maintain the equilibrium.

My feeling is you will never see an annual price increase (or upward adjustment) in HCV pricing. The rare exception could be Sovaldi/GS-5816 in GT3 pending results. Additional combos entering the finite market will continue to drive down prices. Even for GT2/GT3 patients using the stripped down (backbone) Sovaldi/Riba combination.